Improving lives with spidersilk
Seevix was founded in 2014 to revolutionize material science by using spidersilk’s unique natural properties to create innovative high-performance products that improve peoples’ lives.
We are passionate about science. Our remarkable multidisciplinary R&D team of biologists, chemists and engineers strives for cutting-edge innovation.
Dr. Shen has over 20 years of experience in business development executive management roles and R&D at startup and late-stage companies in the life science industry. She has been responsible for advancing products from early-stage research to late-stage development and licensing deals with strategic partners in the US, Europe and Japan. Prior to founding Seevix, Dr. Shen served as CEO of MedAware Ltd., an Israeli healthcare IT company, and as CEO of Fluonic Inc., a US-based medical device company. She advised Israeli and US-based venture capital funds, and performed due diligence related to biotechnology and medical device technologies. Dr. Shen holds a PhD in Biology from Bar-Ilan University and an MBA from Tel Aviv University.
Dr. Hadar is in charge of the day-to-day operations at Seevix. She graduated a two-year, full-time, fellowship program at the Mandel School for Educational Leadership and has strong management skills involving strategic planning, product design and development, and regulatory planning and processes. Prior to joining Seevix, she led regulatory affairs from bench to FDA & CE approvals at Enzysurge. Dr. Hadar holds a BSc in Chemical Engineering and Biology from Ben-Gurion University and an MSc and PhD in Biotechnology from Tel Aviv University.
Mr. Keren heads Seevix’s manufacturing operations and is responsible for the establishment of our large-scale industrial manufacturing facility. Mr. Keren was CEO of several companies, including an aluminum extrusion company that sold products to automotive and train manufacturers, and for the past 20 years has held senior positions in business development, sales and operations at production sites in Romania and Mexico, where he restored profitability. He was responsible for building a manufacturing facility in China and for obtaining ISO certifications for two companies. Mr. Keren holds an MSc in Industrial Engineering and Management from Ben Gurion University.
Dr. Meir guides the technology and research efforts at Seevix. Over the last 18 years he has held different roles in research and product development at several biotech companies, leading groups of up to 20 researchers. Such efforts have yielded commercialized products, more than 20 research papers, and several patents authored by him in the fields of pharmaceuticals and R&D products. Dr. Meir holds a PhD in physiology from the Hebrew University and a postdoc from University College London (UCL) in pharmacology of neurons and their receptors.
Dr. Sklan oversees Seevix’s biology team, which is developing optimization processes, bioassays and 3-dimensional culturing techniques. She has extensive experience in the fields of biology, protein expression, in vitro diagnostics and enzymatic tests. Prior to joining Seevix, she worked as a senior scientist in the in vitro diagnostics field and gained much experience in test development in diverse fields, including virology, microbiology, and cardiovascular systems. She holds a PhD in biochemistry from the Hebrew University.
Dr. Karakouz leads our chemists and material engineers who are developing new materials and products by integrating SVX into various polymers. Over the past six years prior to joining Seevix, she worked at a biomedical device company as a polymers and materials expert in charge of R&D for new products and technologies involving polymers and nanomaterials. Dr. Karakouz holds a PhD in Chemistry from the Weizmann Institute and a postdoc from École Polytechnique Fédérale de Lausanne in Switzerland in biophysical research.